For those taking the highest doses of Biogen’s experimental drug aducanumab, a year of treatment reduced amyloid plaques, in red on the left, a hallmark of Alzheimer’s disease.
For those taking the highest doses of Biogen’s experimental drug aducanumab, a year of treatment reduced amyloid plaques, in red on the left, a hallmark of Alzheimer’s disease. Sevigny et al./Nature TNS
For those taking the highest doses of Biogen’s experimental drug aducanumab, a year of treatment reduced amyloid plaques, in red on the left, a hallmark of Alzheimer’s disease. Sevigny et al./Nature TNS

Alzheimer’s drug offers a bit of hope, but it’s no cure

September 26, 2016 02:13 PM